Publikationen von Julia Sacher
Alle Typen
Zeitschriftenartikel (74)
2011
Zeitschriftenartikel
41 (5), S. 1051 - 1060 (2011)
Relationship of monoamine oxidase A binding to adaptive and maladaptive personality traits. Psychological Medicine 2010
Zeitschriftenartikel
67 (5), S. 468 - 474 (2010)
Elevated brain monoamine oxidase A binding in early postpartum period. Archives of General Psychiatry
Zeitschriftenartikel
2010, 780645 (2010)
Mood disorders are glial disorders: Evidence from in vivo studies. Cardiovascular Psychiatry and Neurology 2009
Zeitschriftenartikel
24 (3), S. 119 - 125 (2009)
Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. International Clinical Psychopharmacology
Zeitschriftenartikel
66 (12), S. 1304 - 1312 (2009)
Brain monoamine oxidase a binding in major depressive disorder: Relationship to selective serotonin reuptake inhibitor treatment, recovery and recurrence. Archives of General Psychiatry 2008
Zeitschriftenartikel
33 (17), S. 1633 - 1641 (2008)
Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 2007
Zeitschriftenartikel
17 (2), S. 102 - 7 (2007)
Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine. Eur Neuropsychopharmacol
Zeitschriftenartikel
191 (2), S. 333 - 9 (2007)
Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology
Zeitschriftenartikel
61 (9), S. 1081 - 9 (2007)
Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry
Zeitschriftenartikel
10 (2), S. 211 - 8 (2007)
Binding kinetics of 123I[ADAM] in healthy controls: a selective SERT radioligand. Int J Neuropsychopharmacol 2006
Zeitschriftenartikel
188 (3), S. 263 - 72 (2006)
In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology 2005
Zeitschriftenartikel
31 (3), S. 1032 - 41 (2005)
Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther. 2004
Zeitschriftenartikel
9 (11), S. 823 - 832 (2004)
Therapy of treatment resistant depression: Focus on the management of TRD with atypical antipsychotics. CNS Spectrums
Zeitschriftenartikel
143 (6), S. :715 - 24 (2004)
Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. Br J Pharmacol. Buchkapitel (2)
2021
Buchkapitel
Time to rethink the default settings in neuroscience: Hormonal transition periods as natural experiments and why sex matters. In: Fundamental questions: Gender dimensions in Max Planck research projects, S. 27 - 42 (Hg. Weber, U.). Nomos, Baden-Baden (2021)
2017
Buchkapitel
Die Rolle von hormonellen Übergangsphasen für Geschlechtsunterschiede in der psychischen Gesundheit. In: Genderperspektiven in der Medizin (GPmed): Abstractband zur Tagungsreihe an der Universität Leipzig, S. 64 - 65 (Hg. Stengler, K.). Pöge, Leipzig (2017)
Meeting Abstract (26)
2024
Meeting Abstract
49 (Suppl. 1), P540, S. 373 - 374. Springer Nature, New York, NY (2024)
Stress markers and brain structure in premenstrual dysphoric disorder and health across the menstrual cycle. In Neuropsychopharmacology, 2023
Meeting Abstract
2 (Suppl. 2), 102798. Elsevier, Amsterdam, The Netherlands (2023)
Obesity and depressive symptoms: Investigating the mediating role of fasting ghrelin serum levels. In Neuroscience Applied, 2022
Meeting Abstract
47 (1), S. 241 - 242. Springer Nature, New York, NY (2022)
Menstrual cycle brain plasticity: Ultra-high field 7 T MRI reveals changes in human medial temporal lobe volume in female adults. In Neuropsychopharmacology, 2021
Meeting Abstract
46 (Suppl. 1), S. 144 - 145. Springer Nature, New York, NY (2021)
Association of maternal mood postpartum with electroencephalography patterns of infant speech development at 2 and 6 months. In Neuropsychopharmacology,